If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Share allotment; Director/PDMR Shareholding; Appt.

15 Jun 2023 07:00

RNS Number : 7676C
Belluscura PLC
15 June 2023
 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU) NO.596/2014, WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"), AS AMENDED.

 

 

15 June 2023

 

Belluscura plc 

("Belluscura", the "Company" or the "Group") 

 

Confirmation of share allotment; Director / PDMR Shareholding; board appointment

 

Confirmation of share allotment

 

Further to the RNS announcement titled "Result of General Meeting" published at 12:28pm on 14 June 2023 Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that 12,386,240 new Ordinary Shares have today been allotted under the Placing, Subscription and Retail Offer.

 

On 25 May 2023, Belluscura announced that pursuant to a Placing and Subscription it has conditionally raised £3.0 million (approximately £2.7 million net of expenses) through the issue of 12,000,000 New Ordinary Shares at the Issue Price of 25 pence per share. The Placing and Subscription have been subscribed for by both new and existing investors.

 

On 1 June 2023, Belluscura announced that pursuant to a Retail Offer to its existing retail shareholders via the BookBuild Platform (the "Retail Offer"), it has conditionally raised c£0.1 million (before expenses) through the issue of 386,240 New Ordinary Shares at the Issue Price of 25 pence per share.

 

The Placing, Subscription and Retail Offer Shares are expected to be admitted to trading on AIM at 8:00 a.m. on or around 16 June 2023.

 

Following Admission, the number of Ordinary Shares in issue and the number of voting rights will be 135,670,067. The figure of 135,670,067 Ordinary Shares may be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Board appointment

 

Further to the RNS announcement titled "Board Appointment" published on 26 May 2023, Bob Fary has been appointed as an executive director with effect from 14 June 2023.

 

Director / PDMR Shareholding

 

As previously notified on 25 May 2023 the Subscribing Directors and Robert Fary have subscribed for 1,992,000 Subscription Shares at the Issue Price of 25 pence, to raise (in aggregate) gross proceeds of £498,000 (before expenses). Details of individual subscriptions are set out in the tables below.

 

Capitalised terms used but not defined herein shall have the same meanings given to them in the announcement of the Proposed Placing and Subscription and Retail Offer Announcements published by the Company on 25 May 2023.

 

For further information please contact:

 

Belluscura plc 

Tel: +44 (0)20 3128 8100 

Adam Reynolds, Chairman 

Robert Rauker, Chief Executive Officer 

Anthony Dyer, Chief Financial Officer 

SPARK Advisory Partners Limited (Nomad)

Tel: +44 (0)20 3368 3550 

Neil Baldwin 

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715 

James Serjeant / Russell Cook 

MHP (Financial PR & Investor Relations)

Tel: +44 (0)20 3128 8100 

Katie Hunt / Matthew Taylor

 belluscura@mhpgroup.com 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

 

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Poutney

2

Reason for notification

a)

Position / status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 

Ordinary shares of £0.01 each in Belluscura plc

ISIN : GB00BD3B8Z11

b)

Nature of the transaction

(i) Acquisition

c)

Price(s) and volumes(s)

Price(s)

Volumes(s)

25p

 

1,800,000

 

 

 

 

 

d)

Aggregated information

n/a

e)

Date of the transaction

25 May 2023

f)

Place of the transaction

London Stock Exchange

 

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Adam Reynolds

2

Reason for notification

a)

Position / status

Non-Executive Chairman

 

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 

Ordinary shares of £0.01 each in Belluscura plc

ISIN : GB00BD3B8Z11

b)

Nature of the transaction

(i) Acquisition

c)

Price(s) and volumes(s)

 

Price(s)

Volumes(s)

25p

80,000

d)

Aggregated information

n/a

e)

Date of the transaction

25 May 2023

f)

Place of the transaction

London Stock Exchange

 

 

 

 

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Robert Rauker

2

Reason for notification

a)

Position / status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): Section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 

Ordinary shares of £0.01 each in Belluscura plc

ISIN : GB00BD3B8Z11

b)

Nature of the transaction

(i) Acquisition

c)

Price(s) and volumes(s)

 

Price(s)

Volumes(s)

25p

 

80,000

 

d)

Aggregated information

n/a

e)

Date of the transaction

25 May 2023

f)

Place of the transaction

London Stock Exchange

 

 

 

 

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Robert Fary

2

Reason for notification

a)

Position / status

Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

Details of the transaction(s): Section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 

Ordinary shares of £0.01 each in Belluscura plc

ISIN : GB00BD3B8Z11

b)

Nature of the transaction

(i) Acquisition

c)

Price(s) and volumes(s)

 

Price(s)

Volumes(s)

25p

 

32,000

 

d)

Aggregated information

n/a

e)

Date of the transaction

25 May 2023

f)

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFETRIISLIV
Date   Source Headline
2nd Dec 20257:00 amRNSCancellation - Belluscura plc
5th Nov 20259:47 amRNSIntention to appoint Administrator Update
31st Oct 202512:15 pmRNSIntention to appoint Administrator
30th Oct 202511:30 amRNSReplacement Statement re US Subsidiary Update
30th Oct 202510:38 amRNSStatement re US Subsidiary Chapter 7 Update
28th Oct 20255:32 pmRNSUpdate re Proposed Fundraise
22nd Sep 20257:00 amRNSDirectorate Change
12th Sep 20254:57 pmRNSBoard Appointment
26th Aug 20256:00 pmRNSSuspended Companies Notice - Deletion
11th Aug 20257:00 amRNSUpdate re Strategic Review and Proposed Fundraise
1st Jul 20257:30 amRNSSuspension - Belluscura PLC
30th Jun 20257:00 amRNSStrategic Review Update and Proposed Fundraising
19th Jun 202511:07 amRNSHolding(s) in Company - Replacement
18th Jun 20255:01 pmRNSHolding(s) in Company
13th May 202512:54 pmRNSResponse to Share Price Movement
9th May 20257:00 amRNSTrading update & commencement of strategic review
16th Apr 20257:00 amRNSTrading Update and Directorate Change
8th Apr 20252:45 pmRNSHolding(s) in Company
8th Apr 20257:00 amRNSStatement re proposed imposition of Tariffs
27th Mar 20253:15 pmRNSHolding(s) in Company
10th Mar 20255:49 pmRNSHolding(s) in Company
6th Mar 20254:21 pmRNSHolding(s) in Company
6th Mar 20251:08 pmRNSHolding(s) in Company
5th Mar 20252:21 pmRNSHolding(s) in Company
4th Mar 20253:50 pmRNSHolding(s) in Company
28th Feb 20253:44 pmRNSReplacement: Result of General Meeting
28th Feb 20251:32 pmRNSResult of General Meeting
13th Feb 20257:30 amRNSHolding(s) in Company
12th Feb 20257:00 amRNSPosting of Circular and Notice of General Meeting
11th Feb 20257:00 amRNSResult of oversubscribed WRAP Retail Offer
7th Feb 20257:05 amRNSLaunch of WRAP Retail Offer
7th Feb 20257:00 amRNSResult of Share Placing
6th Feb 20255:22 pmRNSProposed Share Placing
5th Feb 20257:30 amRNSRule 19.6(c) confirmation of post-offer intentions
20th Dec 20243:20 pmRNSAppointment of Allenby Capital as Joint Broker
11th Dec 20243:21 pmRNSHolding(s) in Company
22nd Nov 20247:00 amRNSNew $4million Credit Facility
12th Nov 20244:34 pmRNSHolding(s) in Company
28th Oct 20247:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
13th Sep 20241:37 pmRNSHolding(s) in Company
12th Sep 20243:05 pmRNSHolding(s) in Company
27th Aug 20242:17 pmRNSResult of General Meeting
27th Aug 20247:00 amRNSAGM Trading Statement
2nd Aug 20247:00 amRNSNotice of AGM
31st Jul 20241:11 pmRNSTotal Voting Rights
19th Jul 202410:36 amRNSDirector/PDMR Shareholding
11th Jul 202411:30 amRNSDirectorate Change
8th Jul 202412:45 pmRNSResult of General Meeting
4th Jul 20241:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.